Biohaven (BHVN), which makes treatments for migraines, is exploring potential options, including a possible sale of the company after drawing interest from suitors, Bloomberg reports, citing people familiar with the matter. The company, which is working with a financial advisor, is in the preliminary stages of weighing a sale or partnership and the talks may not end up in a deal, the report says. Biohaven shares jump 21.5% after the news, while shares of Alder Biopharmaceuticals (ALDR), which also is in the migraine treatment space, were up 4.7%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.